About
Formulex Pharma Innovations continues the activities of SoluBest Ltd in the field of nanotechnology-based drug delivery and formulation. Formulex generates innovative formulation solutions for Israeli and global clients in diversified fields such as biopharmaceuticals, nutraceuticals, and agrochemicals. The formulation development is accompanied by full analytical support and stability studies. Formulex has been developing more than 10 medical cannabis products using its patented Solumer and generic technologies. Five of the products are in the clinical and commercial stages. Solumer was developed by Solubest to maximize the solubility, bioavailability, and physical stability of drug substances utilizing sub-micron-particle engineering. The company designed solid dispersion formulations through a proprietary spray drying process. The technology is proven in preclinical and clinical trials to enhance bioavailability and drug substance performance. Formulex is able to develop and produce under GMP conditions oral, topical, and inhaled dosage forms for clinical phases one and two.
Funding history · 1 round · $55.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Formulex Pharma Innovations' primary focus?
- Formulex Pharma Innovations focuses on nanotechnology-based drug delivery and formulation, developing innovative solutions for clients in biopharmaceuticals, nutraceuticals, and agrochemicals.
- What was Formulex Pharma Innovations formerly known as?
- Formulex Pharma Innovations was formerly known as SoluBest Ltd.
- When was Formulex Pharma Innovations founded?
- Formulex Pharma Innovations was founded in July 2001.
- How many medical cannabis products has Formulex Pharma Innovations developed, and what is their current stage?
- Formulex Pharma Innovations has developed over 10 medical cannabis products using its patented Solumer and generic technologies. Five of these products are currently in clinical and commercial stages.
- What is the purpose of Formulex Pharma Innovations' patented Solumer technology?
- Solumer technology, developed by SoluBest, aims to maximize the solubility, bioavailability, and physical stability of drug substances through sub-micron-particle engineering and a proprietary spray drying process for solid dispersion formulations.
- What types of dosage forms can Formulex Pharma Innovations develop and produce under GMP conditions?
- Formulex Pharma Innovations can develop and produce oral, topical, and inhaled dosage forms under GMP conditions for clinical phases one and two.
- What was the total amount of grant funding received by Formulex Pharma Innovations, and from whom?
- In May 2005, Formulex Pharma Innovations received a grant of $30,000,000 from the IIA.
- When was Dr. Amir Zalcenstein appointed CEO of SoluBest?
- Dr. Amir Zalcenstein, MBA, was appointed CEO of SoluBest in June 2010.
- What is Formulex Pharma Innovations' employee count?
- Formulex Pharma Innovations has between 1 and 10 employees, with an exact count of 5.